1
|
Radecka B, Gełej M, Streb J, Siedlaczek A, Kryka K, Tokajuk P, Winsko-Szczesnowicz K, Czernek U, Sobczak M, Malik M, Bodnar L, Foszczynska-Kloda M, Hetman K, Wełnicka-Jaśkiewicz M, Wierzbicka K, Orlikowska M, Becht R, Deptala A, Itrych B, Kania-Zembaczynska B. P-57 Effectiveness and safety of trifluridine/tipiracil in patients with metastatic colorectal cancer in clinical practice in Poland. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
2
|
Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, Rodriguez-Torres M, Giantonio B, Fox NL, Wissel P, Egger J, Ding M, Kalyani RN, Humphreys R, Gribbin M, Sun W. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Ann Oncol 2016; 27:680-7. [PMID: 26802147 DOI: 10.1093/annonc/mdw004] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 01/07/2016] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND This randomized, double-blind, placebo-controlled, phase II study evaluated the efficacy and safety of mapatumumab (a human agonistic monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 1) in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS Patients with advanced HCC (stratified by Barcelona Clinic Liver Cancer stage and Eastern Cooperative Oncology Group performance status) were randomized 1:1 to receive sorafenib (400 mg, twice daily per 21-day cycle) and either placebo (placebo-sorafenib arm) or mapatumumab (30 mg/kg on day 1 per 21-day cycle; mapatumumab-sorafenib arm). The primary end point was time to (radiologic) progression (TTP), assessed by blinded independent central review. Key secondary end points included progression-free survival, overall survival, and objective response. RESULTS In total, 101 patients were randomized (placebo-sorafenib arm: N = 51; mapatumumab-sorafenib arm: N = 50). There was no significant difference in median TTP between both arms [5.6 versus 4.1 months, respectively; adjusted hazard ratio (one-sided 90% confidence interval) 1.192 (0-1.737)]. No mapatumumab-related benefit was identified when TTP was evaluated in the stratified subgroups. The addition of mapatumumab to sorafenib did not demonstrate improvement in the secondary efficacy end points. The reported frequency of adverse events (AEs) and serious AEs was comparable in both treatment arms. CONCLUSIONS The addition of mapatumumab to sorafenib did not improve TTP or other efficacy end points, nor did it substantially change the toxicity profile of sorafenib in patients with advanced HCC. Based on these results, further development of the combination of mapatumumab and sorafenib in HCC is not planned.
Collapse
Affiliation(s)
- T Ciuleanu
- Department of Medical Oncology, Prof. Dr Ion Chiricuţă Institute of Oncology and UMF Iuliu Hatieganu, Cluj Napoca, Romania
| | - I Bazin
- Federal State Budgetary Institution, Russian Oncology Research Center n.a. N.N. Blokhin under the Russian Academy of Medical Sciences, Moscow, Russia
| | | | - L Miron
- Iasi Regional Institute for Oncology, Iasi County, Romania
| | - I Bondarenko
- Department of Oncology and Medical Radiology, Dnipropetrovsk Medical Academy, City Multispeciality Clinical Hospital # 4, Dnipropetrovsk, Ukraine
| | - A Deptala
- Department of Oncology and Hematology, CSK MSW, Warsaw Department of Cancer Prevention, WNOZ WUM, Warsaw, Poland
| | | | - B Giantonio
- Department of Hematology-Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia
| | - N L Fox
- Clinical Development, Human Genome Sciences, Inc., Rockville
| | - P Wissel
- Clinical Development, GlaxoSmithKline, Upper Providence, USA
| | - J Egger
- Clinical Development, GlaxoSmithKline, Stockley Park, UK
| | - M Ding
- Statistics, GlaxoSmithKline, Upper Providence
| | - R N Kalyani
- Clinical Development, Human Genome Sciences, Inc., Rockville
| | | | - M Gribbin
- Statistics, Human Genome Sciences, Inc., Rockville, USA
| | - W Sun
- Department of Hematology-Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia
| |
Collapse
|
3
|
Palmer D, Meyer T, Chao Y, Deptala A, Fartoux L, Feng YH, Graham J, Lin DY, Ma Y, Peck-Radosavljevic M, Ross P, Ryoo BY, Yen CJ, Hocke J, Vlassak S, Wenz A, Loembe AB, Cheng AL. PD-005 Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv234.04] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Davidenko I, Iveson T, Donehower R, Tjulandin S, Deptala A, Jiang Y, Zhu M, Oliner K, Dubey S, Loh E. Updated Efficacy, Biomarker, and Exposure-Response Data from a Phase 2 Study of Rilotumumab (R) Plus Epirubicin, Cisplatin, and Capecitabine (ECX) in Gastric (G) or Esophagogastric Junction (EGJ) Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33263-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Iveson T, Donehower R, Davidenko I, Tjulandin S, Deptala A, Harrison M, Loh E, Jiang Y, Oliner K, Dubey S. 6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71815-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
van der Meer JWM, van Beem RT, Robak T, Deptala A, Strengers PFW. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. Vox Sang 2011; 101:138-46. [DOI: 10.1111/j.1423-0410.2011.01476.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Rini BI, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Kracht K, Sun Y, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.309] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
309 Background: AMG 386 inhibits angiogenesis by sequestering angiopoietin-1 and -2, thus preventing their interaction with the Tie2 receptor on endothelial cells. Combination with VEGF receptor inhibition has demonstrated additive effects in vivo. The efficacy and tolerability of sorafenib plus AMG 386, an investigational peptide-Fc fusion protein, were evaluated in mRCC pts. Methods: Treatment-naive pts with clear cell mRCC were randomized 1:1:1 to sorafenib 400 mgPO BID plus AMG 386 10 mg/kg (Arm A) or 3 mg/kg (Arm B) QW; or placebo (Arm C) IV QW. Endpoints were progression-free survival (PFS; primary); and (secondary) objective response rate (ORR), change in tumor burden, adverse events (AEs) and pharmacokinetics. Tumor assessment was performed at baseline and every 8 weeks thereafter. Results: 152 pts were randomized: Arms A/B/C, n=50/51/51. 60/61/61% of pts had intermediate and 40/39/37% had low MSKCC risk at baseline. PFS was similar in all 3 arms, whereas ORR was higher in the AMG 386 arms ( Table ). In Arms A/B/C the incidence of grade ≥ 3 AEs was 66/73/86% and serious AEs 36/49/28%. The most common AEs included diarrhea (70/67/56%; grade ≥3 8/10/8%), hand- foot syndrome (52/47/54%; grade ≥3 12/16/28%), alopecia (50/45/50%; grade ≥3 0/0/2%), and hypertension (42/49/46%; grade ≥3 18/20/14%). Median steady-state Cmax and Cmin for AMG 386 were similar to those reported previously. Sorafenib coadministration did not markedly affect AMG 386 exposure. Conclusions: Sorafenib plus AMG 386 was tolerable but did not improve PFS compared with sorafenib plus placebo. Increased ORR and the observed reduction in tumor burden are suggestive of an antitumor effect of AMG 386 in mRCC. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- B. I. Rini
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| | - C. Szczylik
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| | - N. M. Tannir
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| | - P. Koralewski
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| | - P. Tomczak
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| | - A. Deptala
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| | - K. Kracht
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| | - Y. Sun
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| | - M. Puhlmann
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| | - B. Escudier
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Wojskowy Instytut Medyczny, CSK MON Klinika Onkologii, Warszawa, Poland; University of Texas M. D. Anderson Cancer Center, Houston, TX; Wojewodzki Szpital Specjalistyczny im. L. Rydygiera, Krakow, Poland; Samodzielny Publiczny Szpital Kliniczny Numer 1 Imienia Przemienienia Panskiego Akademii Medycznej, Poznan, Poland; Warszawski Uniwersytet Medyczny and Centralny Szpital Kliniczny MSWiA, Warsaw, Poland; Amgen Inc., Thousand Oaks, CA; Institut
| |
Collapse
|
8
|
Hohloch K, Zinzani PL, Linkesch W, Jurczak W, Deptala A, Lorsbach M, Windemuth-Kiesselbach C, Wulf GG, Truemper LH. Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network. Bone Marrow Transplant 2010; 46:901-3. [DOI: 10.1038/bmt.2010.202] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
9
|
Jurczak W, Giza A, Skotnicki AB, Deptala A, Windemuth-Kiesselbach C, Lorsbach M, Suh C, Zinzani PL, Linkesch WM, Trumper LH. Use of radioimmunotherapy for consolidation for chemosensitive mantle cell lymphoma (MCL): Summary of International Radioimmunotherapy Registry data. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18519] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Krzyszton A, Magon M, Omyla-Staszewska J, Asendrych-Wozniak A, Deptala A. Long-term follow-up of efficacy of irinotecan-based chemotherapy in poor-risk patients suffering from metastatic colorectal cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Deptala A, Cedrych I, Polakiewicz-Gilowska A, Nowara E, Domin I. Male breast cancer: An analysis of clinical features, disease outcome and treatment efficacy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Cedrych I, Polakiewicz-Gilowska A, Nowara E, Deptala A. Analysis of long-term outcome and late toxicity in Hodgkin lymphoma survivors. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Deptala A, Magon M, Omyla-Staszewska J, Asendrych A, Paluszewska M. Efficacy and safety of irinotecan-based chemotherapy in poor risk patients suffering from metastatic colorectal cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14581 Background: Irinotecan (CPT11) combination chemotherapy has provided a significant advancement in the management of patients with metastatic colorectal cancer (MCRC). However, there was some data indicating that poor risk cases might not benefit from longer survival with CPT11-based chemotherapy, mainly due to higher regimen toxicity. Purpose: To evaluate the hypothesis, whether CPT-11- based chemotherapy can produce similar TTP and OS in a group of poor risk MCRC patients in comparison to standard risk MCRC cases. Patients and Methods: Out of 170 CRC patients treated in our departments between 2002 - 2006, 36 poor risk MCRC patients (poor risk group was defined as 2 or more criteria being fulfilled, i.e. PS >1, and/or elevated serum LDH, and/or >1 metastatic site, and/or prior adjuvant chemotherapy), were chosen for this analysis and compared retrospectively with our standard risk MCRC cases. The poor risk arm consisted of 9 females and 27 males, in age between 40–76 [median 63,5]. All the patients were treated with CPT11-based chemotherapy, according to either AIO or de Gramont regimen. Results: In the analyzed poor risk group the confirmed RR (CR+PR) after six months of the treatment was 25,0% what was much lower than in standard risk group (RR = 40%), however did not reach the statistical significance; additional 52,8% of patients achieved SD; 8 patients (22,2%) progressed during therapy. The median TTP was 9 months and the median OS was 15 months, what were not statistically different from the standard risk group; 2-year survival obtained 27,8% of patients. No grade (G) 4 toxicity was observed. The most common adverse events (AE) were diarrhea [25% - 9 pts] and neutropenia [11.1% - 4 pts], but G3 AE were noted only in 2 and 1 person respectively. Conclusions: This analysis showed, that CPT11-based chemotherapy is an effective and safe treatment option even for poor risk patients suffering from MCRC. Although the RR was lower in comparison to standard risk cases it did not translate into shorter TTP as well as OS. Similar to ours results were published in various scientific papers. To define a precise role of various optimization strategies of CPT11-based chemotherapy in MCRC, randomized prospective multicenter studies are mandatory. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Deptala
- Central Clinical Hospital Ministry of MSWiA, Zalesie Gorne, Poland; Central Clinical Hospital Ministry of MSWiA, Warsaw, Poland; The Warsaw Medical University, Warsaw, Poland
| | - M. Magon
- Central Clinical Hospital Ministry of MSWiA, Zalesie Gorne, Poland; Central Clinical Hospital Ministry of MSWiA, Warsaw, Poland; The Warsaw Medical University, Warsaw, Poland
| | - J. Omyla-Staszewska
- Central Clinical Hospital Ministry of MSWiA, Zalesie Gorne, Poland; Central Clinical Hospital Ministry of MSWiA, Warsaw, Poland; The Warsaw Medical University, Warsaw, Poland
| | - A. Asendrych
- Central Clinical Hospital Ministry of MSWiA, Zalesie Gorne, Poland; Central Clinical Hospital Ministry of MSWiA, Warsaw, Poland; The Warsaw Medical University, Warsaw, Poland
| | - M. Paluszewska
- Central Clinical Hospital Ministry of MSWiA, Zalesie Gorne, Poland; Central Clinical Hospital Ministry of MSWiA, Warsaw, Poland; The Warsaw Medical University, Warsaw, Poland
| |
Collapse
|
14
|
Chen S, Ruan Q, Bedner E, Deptala A, Wang X, Hsieh TC, Traganos F, Darzynkiewicz Z. Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Prolif 2001; 34:293-304. [PMID: 11591177 PMCID: PMC6496311 DOI: 10.1046/j.0960-7722.2001.00213.x] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Recent studies on the Chinese herbal medicine PC SPES showed biological activities against prostate cancer in vitro, in vivo and in patients with advanced stages of the disease. In investigating its mode of action, we have isolated a few of the active compounds. Among them, baicalin was the most abundant (about 6%) in the ethanol extract of PC SPES, as determined by HPLC. Baicalin is known to be converted in vivo to baicalein by the cleavage of the glycoside moiety. Therefore, it is useful to compare their activities in vitro. The effects of baicalin and baicalein were studied in androgen-positive and -negative human prostate cancer lines LNCaP and JCA-1, respectively. Inhibition of cell growth by 50% (ED(50)) in LNCaP cells was seen at concentrations of 60.8 +/- 3.2 and 29.8 +/- 2.2 microM baicalin and baicalein, respectively. More potent growth inhibitory effects were observed in androgen-negative JCA-1 cells, for which the ED(50) values for baicalin and baicalein were 46.8 +/- 0.7 and 17.7 +/- 3.4, respectively. Thus, it appears that cell growth inhibition by these flavonoids is independent of androgen receptor status. Both agents (1) caused an apparent accumulation of cells in G(1) at the ED(50) concentration, (2) induced apoptosis at higher concentrations, and (3) decreased expression of the androgen receptor in LNCaP cells.
Collapse
Affiliation(s)
- S Chen
- Brander Cancer Research Institute, New York Medical College, Hawthorne, NY 10532, USA.
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Leri A, Barlucchi L, Limana F, Deptala A, Darzynkiewicz Z, Hintze TH, Kajstura J, Nadal-Ginard B, Anversa P. Telomerase expression and activity are coupled with myocyte proliferation and preservation of telomeric length in the failing heart. Proc Natl Acad Sci U S A 2001; 98:8626-31. [PMID: 11447262 PMCID: PMC37486 DOI: 10.1073/pnas.151013298] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The role and even the existence of myocyte proliferation in the adult heart remain controversial. Documentation of cell cycle regulators, DNA synthesis, and mitotic images has not modified the view that myocardial growth can only occur from hypertrophy of an irreplaceable population of differentiated myocytes. To improve understanding the biology of the heart and obtain supportive evidence of myocyte replication, three indices of cell proliferation were analyzed in dogs affected by a progressive deterioration of cardiac performance and dilated cardiomyopathy. The magnitude of cycling myocytes was evaluated by the expression of Ki67 in nuclei. Ki67 labeling of left ventricular myocytes increased 5-fold, 12-fold, and 17-fold with the onset of moderate and severe ventricular dysfunction and overt failure, respectively. Telomerase activity in vivo is present only in multiplying cells; this enzyme increased 2.4-fold and 3.1-fold in the decompensated heart, preserving telomeric length in myocytes. The contribution of cycling myocytes to telomerase activity was determined by the colocalization of Ki67 and telomerase in myocyte nuclei. More than 50% of Ki67-positive cells expressed telomerase in the overloaded myocardium, suggesting that these myocytes were the morphological counterpart of the biochemical assay of enzyme activity. Moreover, we report that 20--30% of canine myocytes were telomerase competent, and this value was not changed by cardiac failure. In conclusion, the enhanced expression of Ki67 and telomerase activity, in combination with Ki67-telomerase labeling of myocyte nuclei, support the notion that myocyte proliferation contributes to cardiac hypertrophy of the diseased heart.
Collapse
Affiliation(s)
- A Leri
- Departments of Medicine, New York Medical College, Valhalla, NY 10595, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Deptala A, Halicka HD, Salomon T, Gorczyca W, Seiter K, Feldman EJ, Traganos F, Darzynkiewicz Z. Malignancy: A New Approach to the Analysis of Apoptosis in the Leukemic Subpopulation by Flow Cytometry Using a CD45 Gating Strategy. Hematology 2001; 4:113-121. [PMID: 11399557 DOI: 10.1080/10245332.1999.11746436] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Bone marrow and peripheral blood are heterogeneous tissues containing cells of different hematopoietic lineages. It is possible to detect leukemic cells by flow cytometry using a gating strategy, which combines CD45 expression on the cell surface with right angle light scatter (SS). This approach was applied to 15 cases of AML. Myeloblasts had the lowest CD45 fluorescence intensity of any of the cells in the myeloid series and also had the lowest SS, approximately equivalent to monocytes, but greater than lymphoblasts and lymphocytes. Using this gating strategy in each sample we could identify up to 5 separate cell compartments. Our results showed good correlation between the flow differential and the manual differential cell count. However in some cases, especially when a sample became hypocellular, the flow differential was more sensitive in identifying leukemic blasts. Total apoptosis (i.e. apoptosis in all cell populations combined) varied during the treatment between 0-34%. In the blood, the highest percentage of total apoptotic cells usually occurred between day 3-5 of treatment. The percentage of apoptotic cells varied depending on the cell type on a percentage basis. The leukemic population was lesslikely to undergo apoptosis compared to the lymphocytes, monocytes and more mature myeloid cells. In normal cells, apoptosis occurred mostly in G(1) and S phases of the cell cycle. Apoptosis among CD45-blasts usually varied between 0-5%. Myeloblasts also had a tendency to undergo apoptosis in G(1) and S phases of the cell cycle. The CD45-blast apoptotic peak in the blood occurred between day 5-7 of treatment. Analysis of drug-induced apoptosis in bone marrow seems to provide more information than such measurements in peripheral blood.
Collapse
Affiliation(s)
- A. Deptala
- Brander Cancer Research Institute, New York Medical College, Valhalla, N.Y. 10595
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Affiliation(s)
- A Deptala
- Brander Cancer Research Institute, New York Medical College, Hawthorne, New York 10532, USA
| | | |
Collapse
|
18
|
Affiliation(s)
- W Gorczyca
- Department of Pathology, New York Medical College, Valhalla 10595, USA
| | | | | | | | | | | |
Collapse
|
19
|
Deptala A, Bedner E, Darzynkiewicz Z. Unique analytical capabilities of laser scanning cytometry (LSC) that complement flow cytometry. Folia Histochem Cytobiol 2001; 39:87-9. [PMID: 11374844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023] Open
Abstract
Flow cytometry has become an indispensable instrumentation in many disciplines of biology and medicine. There are some limitations of flow cytometry, inherent to the fact that the cells are measured in flow, which limit its usefulness in some applications. The microscope-based laser scanning cytometer (LSC) has many features similar to flow cytometry but few restrictions of the latter and therefore it is useful in many new applications. This review briefly outlines the applications that are unique to LSC, particularly related to its morphometric capabilities and the possibility of cell relocation. Potential future applications of LSC are also discussed.
Collapse
Affiliation(s)
- A Deptala
- Department of Hematology, Oncology and Internal Medicine, Medical Academy, Warsaw, Poland.
| | | | | |
Collapse
|
20
|
Kajstura J, Pertoldi B, Leri A, Beltrami CA, Deptala A, Darzynkiewicz Z, Anversa P. Telomere shortening is an in vivo marker of myocyte replication and aging. Am J Pathol 2000; 156:813-9. [PMID: 10702397 PMCID: PMC1876843 DOI: 10.1016/s0002-9440(10)64949-8] [Citation(s) in RCA: 100] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
To determine whether adult cardiac myocytes are capable of multiple divisions and whether this form of growth is restricted to a subpopulation of cells that retain this capacity with age, telomere lengths were measured in myocyte nuclei isolated from the left ventricle of fetal and neonatal Fischer 344 rats and rats at 4, 12, and 27 months after birth. Two independent methodologies were used for this analysis: laser scanning cytometer and confocal microscopy. In each case, fluorescence intensity of a peptide nucleic acid probe specific for telomeric sequence was evaluated. The two techniques yielded comparable results. Telomeric shortening increased with age in a subgroup of myocytes that constituted 16% of the entire cell population. In the remaining nondividing cells, progressive accumulation of a senescent associated nuclear protein, p16(INK4), was evidenced. In conclusion, a significant fraction of myocytes divides repeatedly from birth to senescence, counteracting the continuous death of cells in the aging mammalian rat heart.
Collapse
Affiliation(s)
- J Kajstura
- Department of Medicine, New York Medical College, Valhalla, New York 10595, USA.
| | | | | | | | | | | | | |
Collapse
|
21
|
Seiter K, Feldman EJ, Dorota Halicka H, Deptala A, Traganos F, Burke HB, Hoang A, Goff H, Pozzuoli M, Kancherla R, Darzynkiewicz Z, Ahmed T. Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia. Br J Haematol 2000; 108:40-7. [PMID: 10651722 DOI: 10.1046/j.1365-2141.2000.01804.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
All-trans retinoic acid (ATRA) is synergistic with chemotherapy in leukaemia cell lines. We treated 53 patients with newly diagnosed acute myelogenous leukaemia (AML) with high-dose cytarabine-based chemotherapy followed by ATRA. Peripheral blood and bone marrow samples were obtained to study the effect of in vitro exposure to ATRA and to measure apoptosis and bcl-2. The response rate was 72% for patients under age 60 years and 46% for patients aged 60 years or above. There was no difference in the percentage of responding patients, time to recurrence or overall survival for patients receiving chemotherapy with ATRA vs. historical controls receiving chemotherapy without ATRA. After in vitro exposure of day 3 bone marrow samples to ATRA, there was an increase in apoptotic cells in 25% of patient samples compared with samples not exposed to ATRA. Later date of peak apoptosis in peripheral blood and higher percentage of apoptotic cells in bone marrow on day 3 of treatment were associated with lack of clinical response to treatment. Increased bcl-2 in patient samples was associated with shorter time to recurrence and poor cytogenetic risk. The addition of ATRA to chemotherapy did not improve patient outcome. However, evidence of in vitro response to ATRA in 25% of patients suggests that retinoid pathways should be studied further in patients with AML.
Collapse
Affiliation(s)
- K Seiter
- Zalmen A. Arlin Cancer Institute, Department of Medicine, New York Medical College, Valhalla 10595, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Deptala A, Li X, Bedner E, Cheng W, Traganos F, Darzynkiewicz Z. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin. Int J Oncol 1999; 15:861-71. [PMID: 10536167 DOI: 10.3892/ijo.15.5.861] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The DNA topoisomerase I (topI) inhibitor camptothecin (CPT), stabilizes so-called cleavable complexes which consist of topI covalently attached to 3' OH ends of DNA nicks. Collisions between the progressing DNA replication forks (occurring in S phase cells) or between the transcription driven RNA polymerase molecules (occurring in G1, S and G2 cells) and these complexes convert the latter into secondary DNA lesions which are unrepairable and lethal to the cell. Changes induced by CPT in the level of the tumor suppressor p53, cyclin-dependent kinase inhibitor p21WAF1 and proapoptotic protein Bax (all detected immunocytochemically), were measured separately in the nucleus and cytoplasm of individual human breast carcinoma MCF-7 cells by laser scanning cytometry (LSC) in relation to cell cycle position and induction of apoptosis. The initial transient cell arrest at the G1 checkpoint seen at 8-16 h of treatment with 0.15 microM CPT was accompanied by the rapid accumulation of p53 (preventable by cycloheximide) in the nucleus; the rise (>20-fold) in p53 was maximal for S phase cells. The magnitude of the nuclear p53 increase induced by CPT, at maximum, was 2-fold higher than that induced by the proteasome inhibitor N-acetyl-Leu-Leu-norleucinal (LLnL). While the accumulation of p53 was seen in all phases of the cycle, only G1 cells responded by induction ( approximately 60-fold increase) of p21WAF1. Inhibition of DNA replication by aphidicolin prevented the accumulation of p53 in S and G2/M but had no effect on its induction in G1 cells. Perturbation of cell progression through S phase was seen between 24-72 h of treatment, and it coincided with induction of Bax and apoptosis (both maximal in S phase cells). Thus, the changes observed in S phase cells (nuclear accumulation of p53 preventable by aphidicolin, induction of Bax, apoptosis), triggered by the collisions of DNA replication forks with the CPT-induced lesions, were distinct from the changes in G1 (nuclear p53 accumulation unaffected by aphidicolin, induction of p21WAF1) presumably triggered by collisions of RNA polymerase with the CPT-lesions. Great heterogeneity in expression of p53 and p21WAF1 of the G1 cell population in response to CPT was observed, which may reflect the intercellular variability in the rate of transcription (i.e., frequencies of collisions of RNA polymerase with the lesions). Thus, differences in the transcriptional activity of G1 cells may play a role in their sensitivity to CPT and similar topI inhibitors.
Collapse
Affiliation(s)
- A Deptala
- Brander Cancer Research Institute, New York Medical College, Valhalla, NY 10595, USA
| | | | | | | | | | | |
Collapse
|
23
|
Bedner E, Halicka H, Cheng W, Salomon T, Deptala A, Gorczyca W, Melamed M, Darzynkiewicz Z. High affinity binding of fluorescein isothiocyanate to eosinophils detected by laser scanning cytometry: A potential source of error in analysis of blood samples utilizing fluorescein-conjugated reagents in flow cytometry. ACTA ACUST UNITED AC 1999. [DOI: 10.1002/(sici)1097-0320(19990501)36:1<77::aid-cyto10>3.0.co;2-f] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
24
|
Bedner E, Halicka HD, Cheng W, Salomon T, Deptala A, Gorczyca W, Melamed MR, Darzynkiewicz Z. High affinity binding of fluorescein isothiocyanate to eosinophils detected by laser scanning cytometry: a potential source of error in analysis of blood samples utilizing fluorescein-conjugated reagents in flow cytometry. Cytometry 1999; 36:77-82. [PMID: 10331630 DOI: 10.1002/(sici)1097-0320(19990501)36:1<77::aid-cyto10>3.3.co;2-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND In samples of peripheral blood cells processed using the commercial kits for detection of apoptosis based on DNA strand break labeling, a subpopulation of cells characterized by high green fluorescence, similar in intensity to that of apoptotic cells but more uniform, was consistently observed by flow cytometry. The labeled cells had no other features of apoptosis. The labeling was observed regardless of the fixative used and was evident in control samples lacking terminal deoxynucleotidyltransferase. Common to all the kits that generated this labeling pattern was the presence of fluorescein (f) conjugated reagents, f-dUTP, f-avidin, or f-antibody. METHODS Laser scanning cytometry was used to identify the labeled cells and study the mechanism of labeling. Because it was suspected that the traces of unconjugated f-isothiocyanate (FITC) that may contaminate the reagents were responsible for the labeling, FITC binding affinity to white blood cells was studied. Gel electrophoresis was used to detect the presence of unconjugated FITC in the reagents. RESULTS After staining with Giemsa, the strongly fluorescent objects were identified as eosinophils with normal morphology and no evidence of apoptosis. The fluorescence was localized exclusively within the cytoplasmic granules. Labeling of eosinophils was observed at 2 nM concentration of FITC, which was over three orders of magnitude lower than that needed to label neutrophils, monocytes, or lymphocytes. Gel electrophoresis of the f-conjugated reagents revealed only minor contamination with FITC. CONCLUSIONS (1) Trace amounts of unconjugated FITC contaminating the reagents are adequate to strongly label eosinophils thereby introducing experimental bias in analysis of apoptosis and in other studies on blood cells utilizing f-labeled antibodies, e.g., in detecting cytokines. (2) FITC at concentration 2-500 nM can be used as a marker of eosinophiles; (3) Because of high affinity to FITC, eosinophiles (or the protein from these cells) may serve as a means of removing traces of unconjugated FITC from the reagents during their manufacture or prior to use.
Collapse
Affiliation(s)
- E Bedner
- Brander Cancer Research Institute, New York Medical College, Valhalla, USA
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
Nuclear factor kappa B (NF-kappaB)/rel is the family of ubiquitous transcriptional activators involved in regulation of diverse immune and inflammatory responses. It also plays a role in control of cell growth and apoptosis. In its inactive form NF-kappaB remains in the cytoplasm sequestered through interaction with IkappaB protein. Rapid translocation of NF-kappaB from cytoplasm to nucleus that occurs in response to extracellular signals is considered to be a hallmark feature of its activation. The translocation of NF-kappaB in HL-60, U-937 and Jurkat leukemic cells as well as in human fibroblasts induced by tumor necrosis factor alpha (TNF-alpha) or phorbol myristate acetate (PMA) was presently measured by laser scanning cytometry (LSC). NF-kappaB was detected immunocytochemically with FITC-tagged antibody and its presence in the nucleus vis-a-vis cytoplasm was monitored by measuring the green fluorescence integrated over the nucleus, which was counterstained with propidium iodide (PI), and over the cytoplasm, respectively. Activation of NF-kappaB led to a rapid increase in NF-kappaB-associated fluorescence measured over the nucleus (FN) concomitant with a decrease in fluorescence over the cytoplasm (F(C)), which was reflected by an increase in F(N)/F(C) ratio. This rapid assay of NF-kappaB activation can be combined with morphological identification of the activated cells or with their immunophenotype. Bivariate analysis of NF-kappaB expression versus cellular DNA content makes it possible to correlate its activation with the cell cycle position. The described method has a potential to be used as a functional assay to monitor intracellular translocation of other transcriptional activators such as p53 tumor suppressor protein or signal transduction molecules.
Collapse
Affiliation(s)
- A Deptala
- Brander Cancer Research Institute, New York Medical College, Valhalla, USA
| | | | | | | |
Collapse
|
26
|
Mikulski SM, Viera A, Deptala A, Darzynkiewicz Z. Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. Int J Oncol 1998; 13:633-44. [PMID: 9735389 DOI: 10.3892/ijo.13.4.633] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
In proliferating cells the turnover rate of proteins responsible for regulation of the cell cycle progression, namely cyclins and inhibitors of the cyclin-dependent kinases (CDKs) and phosphatases, is rapid and their cellular level is modulated at the transcriptional, translational and/or degradation (via proteasome pathway) stages. Inhibition of proteasome function results in accumulation of rapidly turning over proteins and, thus, causes an imbalance of the cell cycle regulatory components, and loss of their regulatory function. Indeed, it has been shown that proteasome inhibitors perturb the cell cycle progression. Onconase, a novel RNase which has anti-tumor activity and is in clinical trials, has previously been shown to suppress protein synthesis, presumably by degradation of intracellular RNA, preferentially tRNA. By interfering with regulation of expression of cyclins and/or CDK-inhibitors, onconase also may induce the imbalance of these proteins and potentiate the effect of proteasome inhibitors. In the present study, we observed that the combinations of onconase with peptide-aldehyde inhibitors of calpain and proteasome such as the N-acetyl-leucinyl-leucinyl-norleucinal (LLnL) and the N-acetyl-leucinyl-valinyl-phenylalaninal (LVP), but not N-acetyl-leucinyl-leucinyl-methioninal (LLM), were synergistic in suppressing cell proliferation and inducing apoptosis in three human tumor cell lines: A-549 lung adenocarcinoma, DU-145 prostatic carcinoma, and MDA-MB-231 breast carcinoma. The observed cytotoxicity may also be a result of prevention of the induction of the 'survival' genes by the nuclear factor kappaB (NFkappaB) by onconase and proteasome inhibitors. The data indicate that such combinations should be further tested as potential anti-cancer regimens.
Collapse
|
27
|
Deptala A, Halicka HD, Ardelt B, Ardelt W, Mikulski SM, Shogen K, Darzynkiewicz Z. Potentiation of tumor necrosis factor induced apoptosis by onconase. Int J Oncol 1998; 13:11-6. [PMID: 9625797 DOI: 10.3892/ijo.13.1.11] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Onconase (ONC) a ribonuclease from amphibian oocytes is cytostatic and cytotoxic to many human tumor lines, shows in vivo antitumor activity in mouse tumor models and is in Phase III clinical trials. The mechanism of antitumor activity of ONC is presumed to be due to its internalization, degradation of intracellular RNA and suppression of protein synthesis. Since apoptosis triggered by TNF-alpha is known to be potentiated by inhibitors of protein synthesis, we have hypothesized that it also may be potentiated by ONC. Indeed, preincubation of U-937 or HL-60 leukemic cells with 0.17 microM ONC rendered them more sensitive to induction of apoptosis by TNF-alpha or antibody to CD95 (Fas). The mechanism by which ONC amplifies the effect of TNF-alpha may involve suppression of induction of the survival genes whose expression is triggered by activation of NFkB by this factor.
Collapse
Affiliation(s)
- A Deptala
- Brander Cancer Research Institute, New York Medical College, Valhalla, NY 10595, USA
| | | | | | | | | | | | | |
Collapse
|